CAT #: 20960021
Specimen Control Size Ladder - 6FAM for ABI Fluorescence Detection
The General Purpose Reagent (GPR) Specimen Control Size Ladder master mix can be used to ensure that the quantity and quality of unknown sample DNA is adequate to yield a valid result during molecular testing.
Summary and Explanation of the Test
Sample quality is critical and therefore it must be verified before the samples are used in molecular assays. Analysis of degraded DNA samples can result in poor quality data, and the presence of inhibitors differentially affects qPCR assays.1,2 Therefore, verification of the quantity and quality of the sample is sufficient for the molecular assay is important, and one method is to employ an amplification control master mix.
Master mixes are components of complete assays and typically consist of a buffered magnesium solution, deoxynucleotides, and multiple primers that target the gene segments of interest. Multiple primers are used to ensure a more comprehensive testing approach necessary to reliably identify clonal rearrangements. This test is complete with the exception of Taq DNA polymerase, which is not provided.
The Specimen Control Size Ladder master mix is included in many of our testing kits and targets four different genes: Tbxas (thromboxane synthase), RAG-1 (recombination activating gene-1), PLZF (promyelocytic leukemia zinc finger) and AF4 (ALL1 fused gene from chromosome 4). Amplification of genomic DNA (gDNA) with this master mix produces products of 100, 200, 300, 400, and 600 base pairs (bp) to ensure that the quality and quantity of the sample DNA is adequate to yield a valid result.
This master mix tests genomic DNA (gDNA) from the following sources:
- 5 cc of peripheral blood, bone marrow biopsy or bone marrow aspirate anti-coagulated with heparin or EDTA. Ship at ambient temperature; OR
- Minimum 5 mm cube of tissue shipped frozen; or at room temperature or on ice in RPMI 1640; OR
- 2 µg of gDNA; OR
- Formalin-fixed paraffin embedded tissue or slides
1. Vermeulen J et al. (2011) Nucleic Acids Research. May;39(9):e63.
2. Huggett JF et al. (2008) BMC Research Notes. Aug 28;1:70.
This assay is based on the EuroClonality/BIOMED-2 Concerted Action BMH4-CT98-3936.
Warranty and Liability
Invivoscribe, Inc. (Invivoscribe®) is committed to providing the highest quality products. Invivoscribe® warrants that the products meet or exceed the performance standards described in the Instructions For Use, as to products with such an insert. If a product is covered by product specifications and does not perform as specified, our policy is to replace the product or credit the full purchase price. No other warranties of any kind, expressed or implied, are provided by Invivoscribe®. Invivoscribe® liability shall not exceed the purchase price of the product. Invivoscribe® shall have no liability for direct, indirect, consequential or incidental damages arising from the use, results of use, or inability to use its products; product efficacy under purchaser controlled conditions in purchaser’s laboratory must be established and continually monitored through purchaser defined and controlled processes including but not limited to testing of positive, negative, and blank controls every time a sample is tested. Ordering, acceptance, and use of product constitutes purchaser acceptance of sole responsibility for assuring product efficacy and purchaser agreement to the limitation of liability set forth in this paragraph.
This product is for Research Use Only; not for use in diagnostic procedures.
This product is covered by one or more of the following: European Patent Number 1549764, European Patent Number 2418287, European Patent Number 2460889, Japanese Patent Number 4708029, United States Patent 8859748, United States Patent 10280462, and related pending and future applications. All of these patents and applications are licensed exclusively to Invivoscribe®. Additional patents licensed to Invivoscribe® covering some of these products apply elsewhere. Many of these products require nucleic acid amplification methods such as Polymerase Chain Reaction (PCR). No license under these patents to use amplification processes or enzymes is conveyed expressly or by implication to the purchaser by the purchase of this product.
©2020 Invivoscribe, Inc. All rights reserved. The trademarks mentioned herein are the property of Invivoscribe, Inc. and/or its affiliates, or (as to the trademarks of others used herein) their respective owners.